Form 4: Verrica Pharmaceuticals CFO Terry Kohler Receives Stock Options and Restricted Stock Units

Verrica Pharmaceuticals' CFO, Terry Kohler, was granted stock options and restricted stock units on March 15, 2024, as reported in a Form 4 filing with the SEC.

Summary

• Terry Kohler, CFO of Verrica Pharmaceuticals, received 40,000 restricted stock units (RSUs) and options to purchase 80,000 shares of common stock on March 15, 2024.
• The RSUs vest in equal annual installments on March 15 of 2025, 2026, 2027, and 2028, contingent upon continuous service.
• The stock options have an exercise price of $4.80 and vest 25% on March 15, 2025, with the remaining portion vesting monthly over the subsequent three years, also subject to continuous service.
• Following these transactions, Kohler directly owns 74,416 shares of Verrica Pharmaceuticals common stock and options to purchase 80,000 shares.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed neutrally to positively as it aligns management interests with shareholders. The sentiment is moderately positive due to the incentive structure created for the CFO.

Positives

• The grant of RSUs and stock options to the CFO aligns his interests with those of the shareholders, incentivizing him to improve the company's performance.
• The vesting schedules of the RSUs and stock options encourage long-term commitment from the CFO.

Industry Context

Stock option and RSU grants are a common practice in the pharmaceutical industry to attract and retain key executives. The vesting schedules are designed to align management's interests with the long-term success of the company.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the pharmaceutical industry.
• Companies like Amgen, Gilead Sciences, and Regeneron Pharmaceuticals also utilize stock options and RSUs to incentivize their executives.
• The vesting schedules described are typical, with vesting periods ranging from three to five years.

Stakeholder Impact

• Shareholders may view the grant of stock options and RSUs positively as it incentivizes the CFO to improve company performance.
• Employees may see this as a positive sign of the company's commitment to its leadership.

Key Dates